Bio Rad Outlines Its Advances Leveraging Droplet Digital Pcr In Bio rad is reaching a comprehensive range of laboratories through its strategic collaborations — from academic centers to integrated health networks to service providers — with the goal of enabling clinical evidence generation using best in kind droplet digital pcr to advance precision oncology. Together with bio rad’s existing line of qx200™ and qx600™ ddpcr systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital pcr products for life science research and diagnostic applications.
Bio Rad Outlines Its Advances Leveraging Droplet Digital Pcr In Bio rad laboratories, inc. (nyse: bio and bio.b), a global leader in life science research and clinical diagnostics products, today announced the launch of four new droplet digital™ pcr (ddpcr™) platforms. Discover bio rad’s expanded droplet digital pcr portfolio, including the new qx continuum and qx700 series systems, offering unmatched precision, high throughput, and multiplexing for genomics, oncology, and diagnostic research. Bio rad laboratories has expanded its droplet digital pcr (ddpcr) product portfolio with four new platforms, including the qx continuum and qx700 series, enhancing its capabilities in genomics research and diagnostics. Bio rad laboratories, inc., a global leader in life science research and clinical diagnostics products, has announced the launch of four new droplet digital™ pcr (ddpcr™) platforms.
Droplet Digital Pcr For Every Lab Every Budget Bio Rad Bio rad laboratories has expanded its droplet digital pcr (ddpcr) product portfolio with four new platforms, including the qx continuum and qx700 series, enhancing its capabilities in genomics research and diagnostics. Bio rad laboratories, inc., a global leader in life science research and clinical diagnostics products, has announced the launch of four new droplet digital™ pcr (ddpcr™) platforms.
Comments are closed.